青松股份(300132.SZ):終止諾斯貝爾148畝大型產業園區項目建設暨與政府部門協商收回土地使用權
格隆匯4月12日丨青松股份(300132.SZ)公佈,受宏觀經濟、行業環境等因素影響,2021年以來公司化粧品業務訂單增長不及預期,前期新增產能短期未能得到釋放,導致公司化粧品ODM業務產能利用率較低,短期大規模擴產需求放緩。董事會對148畝土地項目進行了充分討論,認為在化粧品行業未全面復甦的背景下,終止148畝土地項目建設,並與政府部門協商有償收回土地使用權,有利於公司降低生產經營成本,減輕資金壓力,降低公司借款規模和資產負債率,符合公司在行業環境未明顯好轉的情況下實施降本增效、努力提升生產效益的經營目標。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.